BMS363 Clinical Biochemistry 2 (6)

This subject is a continuation of Clinical Biochemistry 1 and covers techniques in measurements of endogenous and exogenous metabolites found in low levels in biological specimens. These metabolites include (but are not limited to), hormones and drugs that are used in therapy and/or that are abused. Techniques inclusive of the various types of immunoassays as well as mass spectrometry are therefore covered. Monogenic diseases are learnt with emphasis on cystic fibrosis and phenylketonuria. Clinical endocrinology is studied and various endocrine disorders are emphasised to illustrate development of endocrine diseases and the importance of clinical biochemistry in diagnosis and management of endocrine disorders. On completion of this subject, a student is equipped with theoretical skills for clinical biochemical investigation of endocrine disorders, monogenic diseases and drugs. Such knowledge is useful for example in further studies in this discipline and also other disciplines such as forensic sciences, dentistry, medicine and veterinary as well as animal sciences, routine and specialist pathology, research and in industry that develops and/or supplies diagnostic technology and consumables.


Micro Session 5 (72)
On Campus
Wagga Wagga Campus
Wagga Wagga Campus

Continuing students should consult the SAL for current offering details: BMS363. Where differences exist between the Handbook and the SAL, the SAL should be taken as containing the correct subject offering details.

Subject Information

Grading System



One session


School of Biomedical Sciences



Subject Relationships

BMS302 BMS363 is equivalent to BMS302 without the laboratory practicals

Incompatible Subjects


Learning Outcomes

Upon successful completion of this subject, students should:
  • be able to describe and evaluate the various techniques (including but not limited to recognition techniques and mass spectrometry) utilised in measurement of endogenous metabolites and drugs found in low concentrations in biological fluids/tissues in various diseases;
  • be able to interpret results/data in measurement of drugs and in diagnosis and management of endocrine and monogenic diseases;
  • be able to describe how endocrine diseases and monogenic diseases (e.g. cystic fibrosis and phenylketonuria) arise and to describe and evaluate the patho-biochemical/patho-physiological rationale for screening, diagnosis and management of these diseases;
  • be able to describe and analyse the rationale for measuring drugs and describe pharmacokinetic principles and their importance to clinical biochemistry;
  • be able to describe and evaluate toxicological exposure involving chemicals and metals; and
  • be able to work independently and collaboratively in measurement of analyses and to write a scientific report on experimental findings and data interpretation.


This subject will cover the following topics:
  • Paediatric clinical biochemistry with emphasis on human monogenic disorders;
  • Endocrine diseases;
  • Endocrine control of calcium, phosphate and magnesium levels and changes to this control in disease;
  • Therapeutic and drugs of abuse; and
  • Techniques (theory) including, but not limited to chemical, immunoassays, chromatographic and mass spectrometry used in investigations and management of endocrine and monogenic diseases and in measurement of ions and drugs.

The information contained in the CSU Handbook was accurate at the date of publication: May 2021. The University reserves the right to vary the information at any time without notice.